Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
WST Stock Forecast 2026-2027
$278.00
Current Price
$20.04B
Market Cap
Buy 12
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to WST Price Targets
+34.9%
To High Target of $375.00
+13.3%
To Median Target of $315.00
-1.1%
To Low Target of $275.00
WST Price Momentum
+3.8%
1 Week Change
+17.3%
1 Month Change
+35.0%
1 Year Change
+1.0%
Year-to-Date Change
-13.8%
From 52W High of $322.34
+39.1%
From 52W Low of $199.89
📊 TOP ANALYST CALLS
Did WST Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if West Pharmaceutical is one of their latest high-conviction picks.
Latest WST Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, WST has a bullish consensus with a median price target of $315.00 (ranging from $275.00 to $375.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $278.00, the median forecast implies a 13.3% upside. This outlook is supported by 12 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from John Sourbeer at UBS, projecting a 34.9% upside. Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 1.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
WST Analyst Ratings
12
Buy
3
Hold
0
Sell
WST Price Target Range
Low
$275.00
Average
$315.00
High
$375.00
Current: $278.00
Latest WST Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for WST.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 14, 2026 | Barclays | Luke Sergott | Equal-Weight | Maintains | $275.00 |
| Feb 13, 2026 | Barclays | Luke Sergott | Equal-Weight | Maintains | $265.00 |
| Feb 3, 2026 | Evercore ISI Group | Daniel Markowitz | Outperform | Maintains | $320.00 |
| Dec 2, 2025 | Morgan Stanley | Kallum Titchmarsh | Equal-Weight | Initiates | $285.00 |
| Oct 29, 2025 | TD Cowen | Brendan Smith | Buy | Initiates | $350.00 |
| Oct 27, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $325.00 |
| Oct 24, 2025 | Keybanc | Paul Knight | Overweight | Maintains | $350.00 |
| Oct 24, 2025 | UBS | John Sourbeer | Buy | Maintains | $355.00 |
| Oct 23, 2025 | Evercore ISI Group | Daniel Markowitz | Outperform | Maintains | $390.00 |
| Oct 2, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $275.00 |
| Sep 15, 2025 | Rothschild & Co | Jamie Clark | Buy | Initiates | $311.00 |
| Jul 25, 2025 | UBS | John Sourbeer | Buy | Maintains | $320.00 |
| Jul 25, 2025 | Barclays | Equal-Weight | Maintains | $N/A | |
| Jul 25, 2025 | Evercore ISI Group | Daniel Markowitz | Outperform | Maintains | $350.00 |
| Jun 24, 2025 | Barclays | Luke Sergott | Equal-Weight | Initiates | $245.00 |
| Mar 18, 2025 | Evercore ISI Group | Daniel Markowitz | Outperform | Initiates | $275.00 |
| Feb 14, 2025 | Keybanc | Paul Knight | Overweight | Maintains | $325.00 |
| Jan 8, 2025 | Citigroup | Thomas Palmer | Buy | Initiates | $400.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $355.00 |
| Dec 13, 2024 | Wolfe Research | Doug Schenkel | Peer Perform | Initiates | $N/A |
West Pharmaceutical Services, Inc. (WST) Competitors
The following stocks are similar to West Pharmaceutical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
WST
West Pharma
mkt cap
19.73B
West Pharmaceutical Services, Inc. (WST) Financial Data
West Pharmaceutical Services, Inc. has a market capitalization of $20.04B with a P/E ratio of 40.3x. The company generates $3.07B in trailing twelve-month revenue with a 16.1% profit margin.
Revenue growth is +7.5% quarter-over-quarter, while maintaining an operating margin of +21.6% and return on equity of +16.9%.
Valuation Metrics
Market Cap
$20.04B
Enterprise Value
$19.25B
P/E Ratio
40.3x
PEG Ratio
18.0x
Price/Sales
6.4x
Growth & Margins
Revenue Growth (YoY)
+7.5%
Gross Margin
+37.8%
Operating Margin
+21.6%
Net Margin
+16.1%
EPS Growth
+1.5%
Financial Health
Cash/Price Ratio
+4.0%
Current Ratio
3.0x
Debt/Equity
10.3x
ROE
+16.9%
ROA
+10.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
West Pharmaceutical Services, Inc. (WST) Business Model
About West Pharmaceutical Services, Inc.
What They Do
Designs and manufactures drug packaging solutions.
Business Model
The company generates revenue through its Proprietary Products and Contract-Manufactured Products segments, focusing on the production of drug packaging and delivery systems for the pharmaceutical and biotechnology industries. It provides a range of solutions including elastomeric and polymer components, along with design, testing, and regulatory support to help clients accelerate product development while ensuring compliance with quality standards.
Additional Information
Founded in 1923 and based in Exton, Pennsylvania, the company has a global presence with manufacturing facilities and R&D centers in North America, Europe, and Asia-Pacific. West Pharmaceutical Services collaborates with leading drug firms to enhance patient safety and improve healthcare delivery.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
10,800
CEO
Mr. Eric M. Green
Country
United States
IPO Year
1988
Website
www.westpharma.comWest Pharmaceutical Services, Inc. (WST) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now
WST rides strong HVP demand and GLP-1 expansion, but tariffs, destocking pressures and European facility constraints pose near-term growth risks.
Apr 16, 2026
By Zacks Equity Research
Analyst Blog
West Pharmaceutical Services (WST) Reports Next Week: Wall Street Expects Earnings Growth
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 16, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
West Pharmaceutical Services (WST) Reports Next Week: Wall Street Expects Earnings Growth
4 days ago
Quick Summary
West Pharmaceutical (WST) is expected to report earnings that may exceed estimates, driven by strong factors. Investors should stay informed for the upcoming report.
Why It Matters
West Pharmaceutical's potential earnings beat indicates strong financial performance, possibly boosting stock prices and investor confidence in the company.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
WST is benefiting from high-volume product demand and GLP-1 expansion, but faces near-term growth risks from tariffs, destocking, and European facility constraints.
Why It Matters
WST's strong demand and GLP-1 expansion signal growth potential, but tariffs and operational challenges may hinder short-term performance, affecting stock stability.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
The portfolio shifted focus to companies with resilient business models, investing in Dick's Sporting Goods and exiting Ares Management due to liquidity and credit concerns affecting private credit.
Why It Matters
Shifting investments towards companies with stable growth prospects and away from vulnerable sectors signals a proactive strategy, potentially enhancing returns in uncertain market conditions.
Source: Seeking Alpha
Market Sentiment:
Positive
West to Host First-Quarter 2026 Conference Call
12 days ago
Quick Summary
West Pharmaceutical Services, Inc. (NYSE: WST) will release Q1 2026 financial results on April 23, 2026, before market open, followed by a conference call at 8:00 a.m. ET.
Why It Matters
West Pharmaceutical's upcoming earnings release can impact stock performance and investor sentiment, as it provides insights into financial health and future growth prospects.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors in the Medical - Dental Supplies sector may consider Align Technology (ALGN) and West Pharmaceutical Services (WST) for potential value opportunities.
Why It Matters
The comparison of Align Technology and West Pharmaceutical Services highlights potential investment opportunities in the Medical - Dental Supplies sector, guiding value-focused decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
20 days ago
Quick Summary
West Pharmaceutical Services (NYSE: WST) opened a 165,000 sq. ft. facility in Dublin to enhance contract services, addressing rising demand for injectable treatments like diabetes and obesity.
Why It Matters
West Pharmaceutical's expansion signals increased capacity to meet rising demand in the injectable drug market, potentially boosting revenue and market share, which is favorable for investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About WST Stock
What is West Pharmaceutical Services, Inc.'s (WST) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, West Pharmaceutical Services, Inc. (WST) has a median price target of $315.00. The highest price target is $375.00 and the lowest is $275.00.
Is WST stock a good investment in 2026?
According to current analyst ratings, WST has 12 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $278.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for WST stock?
Wall Street analysts predict WST stock could reach $315.00 in the next 12 months. This represents a 13.3% increase from the current price of $278.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is West Pharmaceutical Services, Inc.'s business model?
The company generates revenue through its Proprietary Products and Contract-Manufactured Products segments, focusing on the production of drug packaging and delivery systems for the pharmaceutical and biotechnology industries. It provides a range of solutions including elastomeric and polymer components, along with design, testing, and regulatory support to help clients accelerate product development while ensuring compliance with quality standards.
What is the highest forecasted price for WST West Pharmaceutical Services, Inc.?
The highest price target for WST is $375.00 from John Sourbeer at UBS, which represents a 34.9% increase from the current price of $278.00.
What is the lowest forecasted price for WST West Pharmaceutical Services, Inc.?
The lowest price target for WST is $275.00 from Luke Sergott at Barclays, which represents a -1.1% decrease from the current price of $278.00.
What is the overall WST consensus from analysts for West Pharmaceutical Services, Inc.?
The overall analyst consensus for WST is bullish. Out of 15 Wall Street analysts, 12 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $315.00.
How accurate are WST stock price projections?
Stock price projections, including those for West Pharmaceutical Services, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 4:14 AM UTC